Abstract

The HCV-RNA (Hepatitis-C RNA) diagnosed patients are recommended interferon free Direct-Acting Antiviral (DAAs) therapy. Although the treated patients are reported viral resistance to DAAs, the genotype 3a infection is challenge to NS5A inhibitors leading to cirrhosis. Therefore, the patients with chronic Hepatitis-C treated with DAAs, nucleotide analogue inhibitors or NS5B protein have high risk of resistance. Breakthrough or relapse is not common with these drugs when used as monotherapy.NS3-4A protease inhibitors and non-nucleoside inhibitors have low susceptibility to resistance. Sofosbuvir-resistant variants have been discovered that disappear after treatment withdrawal. Patients who experience relapse after an INF-free treatment have large fraction of drug resistant viruses.